A Multicenter Randomized Phase IIb Efficacy Study of Vx-001, a Peptide-Based Cancer Vaccine as Maintenance Treatment in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics

• Published in: Clinical lung cancer Vol. 14; no. 4; pp. 461 - 465
• Main Authors: Georgoulias, Vassilis, Douillard, Jean-Yves, Khayat, David, Manegold, Christian, Rosell, Rafael, Rossi, Antonio, Menez-Jamet, Jeanne, Iché, Marina, Kosmatopoulos, Kostas, Gridelli, Cesare
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2013
• Subjects: Adolescent; Cancer Vaccines - therapeutic use; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - therapy; Clinical trial; Double-Blind Method; First-line; Follow-Up Studies; Hematology, Oncology and Palliative Medicine; Humans; International Agencies; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Metastatic/recurrent non–small-cell lung cancer (NSCLC); Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; Neoplasm Staging; Peptide Fragments - therapeutic use; Prognosis; Pulmonary/Respiratory; Telomerase - therapeutic use; Telomerase reverse transcriptase (TERT); Vaccination; Clinical trial; First-line; Metastatic/recurrent non–small-cell lung cancer (NSCLC); Telomerase reverse transcriptase (TERT); Vaccination
• ISSN: 1525-7304; 1938-0690
• DOI: 10.1016/j.cllc.2013.02.001

Abstract We present the treatment rationale and study design of a multicenter, open-label, randomized, 2-arm, phase IIb study. Patients with stage IV or recurrent stage I to III non–small-cell lung cancer (NSCLC) whose disease does not progress after 4 cycles of first-line platinum-based chemotherapy will be randomized in a 1:1 ratio to 1 of 2 study arms. Patients will receive the cancer vaccine Vx-001 + Montanide ISA51 VG (Seppic, Paris, France) adjuvant subcutaneously, at a dose of 2 mg, or placebo + Montanide ISA51 VG adjuvant subcutaneously. The vaccination protocol comprises 2 injections with the TYR-Vx001 or placebo (1 at day 0 and another at week 3) and 4 injections with the ARG-Vx001 or placebo, at weeks 6, 9, 12, and 15. After the treatment assessment at week 18, patients will receive the ARG-Vx001 or placebo every 12 weeks starting from week 27 until disease progression, unacceptable toxicity, withdrawal of informed consent, or death. The primary end point of this study is the survival rate at 12 months. Secondary end points include time-to-event comparison of overall survival and comparison of time to treatment failure. Exploratory objectives include comparison of disease control rate after the end of subsequent second-line treatments, comparisons of vaccine immune responses, comparison of survival rate at 12 months in patients with vaccine-induced immune response detected after the second and sixth injections, identification of biomarkers on lymphocytes and on tumors, and comparison of safety and tolerability.